108 related articles for article (PubMed ID: 35385169)
1. Buprenorphine treatment retention and comorbidities among patients with opioid use disorder in a primary care setting.
Sweeney MM; Prichett L; Fingerhood MI; Antoine D; Umbricht A; Dunn KE; Buresh ME
Am J Addict; 2022 May; 31(3):256-260. PubMed ID: 35385169
[TBL] [Abstract][Full Text] [Related]
2. Buprenorphine treatment outcomes among opioid-dependent cocaine users and non-users.
Cunningham CO; Giovanniello A; Kunins HV; Roose RJ; Fox AD; Sohler NL
Am J Addict; 2013; 22(4):352-7. PubMed ID: 23795874
[TBL] [Abstract][Full Text] [Related]
3. Long-term retention in Office Based Opioid Treatment with buprenorphine.
Weinstein ZM; Kim HW; Cheng DM; Quinn E; Hui D; Labelle CT; Drainoni ML; Bachman SS; Samet JH
J Subst Abuse Treat; 2017 Mar; 74():65-70. PubMed ID: 28132702
[TBL] [Abstract][Full Text] [Related]
4. Nine-year substance use treatment outcomes with buprenorphine for opioid use disorder in a federally qualified health center.
Haddad M; Coman E; Bifulco L
Drug Alcohol Depend; 2024 Apr; 257():111252. PubMed ID: 38484404
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C Virus Testing and Treatment Among Persons Receiving Buprenorphine in an Office-Based Program for Opioid Use Disorders.
Carey KJ; Huang W; Linas BP; Tsui JI
J Subst Abuse Treat; 2016 Jul; 66():54-9. PubMed ID: 26988423
[TBL] [Abstract][Full Text] [Related]
6. Associations of retention on buprenorphine for opioid use disorder with patient characteristics and models of care in the primary care setting.
Bailey SR; Lucas JA; Angier H; Cantone RE; Fleishman J; Garvey B; Cohen DJ; Rdesinski RE; Gordon L
J Subst Abuse Treat; 2021 Dec; 131():108548. PubMed ID: 34244013
[TBL] [Abstract][Full Text] [Related]
7. A naturalistic study of predictors of retention in treatment among emerging adults entering first buprenorphine maintenance treatment for opioid use disorders.
Dayal P; Balhara YPS
J Subst Abuse Treat; 2017 Sep; 80():1-5. PubMed ID: 28755768
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of primary care delivered buprenorphine treatment retention outcomes.
Cooper RL; Edgerton RD; Watson J; Conley N; Agee WA; Wilus DM; MacMaster SA; Bell L; Patel P; Godbole A; Bass-Thomas C; Ramesh A; Tabatabai M
Am J Drug Alcohol Abuse; 2023 Nov; 49(6):756-765. PubMed ID: 37737714
[No Abstract] [Full Text] [Related]
9. Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration.
Lin LA; Bohnert ASB; Blow FC; Gordon AJ; Ignacio RV; Kim HM; Ilgen MA
Addiction; 2021 Jan; 116(1):96-104. PubMed ID: 32428386
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and treatment of opioid use disorders among primary care patients in six health systems.
Lapham G; Boudreau DM; Johnson EA; Bobb JF; Matthews AG; McCormack J; Liu D; Samet JH; Saxon AJ; Campbell CI; Glass JE; Rossom RC; Murphy MT; Binswanger IA; Yarborough BJH; Bradley KA;
Drug Alcohol Depend; 2020 Feb; 207():107732. PubMed ID: 31835068
[TBL] [Abstract][Full Text] [Related]
11. A Descriptive analysis of urine drug screen results in patients with opioid use disorder managed in a primary care setting.
Sobel HG; Warrington JS; Francis-Fath S; Crocker AM; Berger CA
Addict Sci Clin Pract; 2021 Sep; 16(1):59. PubMed ID: 34593036
[TBL] [Abstract][Full Text] [Related]
12. Associations between prescribed benzodiazepines, overdose death and buprenorphine discontinuation among people receiving buprenorphine.
Park TW; Larochelle MR; Saitz R; Wang N; Bernson D; Walley AY
Addiction; 2020 May; 115(5):924-932. PubMed ID: 31916306
[TBL] [Abstract][Full Text] [Related]
13. Trauma treatment for veterans in buprenorphine maintenance treatment for opioid use disorder.
Meshberg-Cohen S; Black AC; DeViva JC; Petrakis IL; Rosen MI
Addict Behav; 2019 Feb; 89():29-34. PubMed ID: 30243036
[TBL] [Abstract][Full Text] [Related]
14. Treatment retention in opioid agonist therapy: comparison of methadone versus buprenorphine/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province.
Sadek J; Saunders J
BMC Psychiatry; 2022 Jul; 22(1):516. PubMed ID: 35908052
[TBL] [Abstract][Full Text] [Related]
15. A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia.
Burns L; Gisev N; Larney S; Dobbins T; Gibson A; Kimber J; Larance B; Mattick RP; Butler T; Degenhardt L
Addiction; 2015 Apr; 110(4):646-55. PubMed ID: 25516077
[TBL] [Abstract][Full Text] [Related]
16. Three-year retention in buprenorphine treatment for opioid use disorder nationally in the Veterans Health Administration.
Manhapra A; Petrakis I; Rosenheck R
Am J Addict; 2017 Sep; 26(6):572-580. PubMed ID: 28472543
[TBL] [Abstract][Full Text] [Related]
17. Timing of hepatitis C treatment initiation and retention in office-based opioid treatment with buprenorphine: a retrospective cohort study.
Geist ML; Radick AC; Tsui JI; Blalock KL; Adwell A; Tamru E; Connolly NC; James JR
Addict Sci Clin Pract; 2023 May; 18(1):33. PubMed ID: 37231486
[TBL] [Abstract][Full Text] [Related]
18. Three-Year Retention in Buprenorphine Treatment for Opioid Use Disorder Among Privately Insured Adults.
Manhapra A; Agbese E; Leslie DL; Rosenheck RA
Psychiatr Serv; 2018 Jul; 69(7):768-776. PubMed ID: 29656707
[TBL] [Abstract][Full Text] [Related]
19. Same-day vs. delayed buprenorphine prescribing and patient retention in an office-based buprenorphine treatment program.
Jakubowski A; Lu T; DiRenno F; Jadow B; Giovanniello A; Nahvi S; Cunningham C; Fox A
J Subst Abuse Treat; 2020 Dec; 119():108140. PubMed ID: 33138925
[TBL] [Abstract][Full Text] [Related]
20. A systematic review of sex differences in treatment outcomes among people with opioid use disorder receiving buprenorphine maintenance versus other treatment conditions.
Ling S; Mangaoil R; Cleverley K; Sproule B; Puts M
Drug Alcohol Depend; 2019 Apr; 197():168-182. PubMed ID: 30831429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
